Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697187 · ClinicalTrials.gov registry record
Patient Registry to Evaluate the Real-world Safety of Ruconest®
A clinical trial, sponsored by Pharming Technologies B.V..
- Completed
- Registry status
- 152
- Enrollment target
NCT03697187: Completed study, sponsored by Pharming Technologies B.V..
NCT03697187 is a clinical trial that has completed, run by Pharming Technologies B.V.. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03697187 has completed, sponsored by Pharming Technologies B.V..
- COMPLETED
- Registry status
- 152 participants
- Enrollment target
Study Summary
This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.
Primary Outcome
In addition, extent of exposure to Ruconest and concomitant medications taken for HAE will be summarized. Concomitant medications will be limited to those specifically indicated for treatment AEs or treatment of symptoms of HAE, for example C1-inhibitors, epinephrine, IV fluids, etc. AEs will be summarized as incidence per 10,000 person-days where each patient counts only once for multiple events of the same System Organ Class and preferred terms within the 30-day evaluation period. The person-t
Interventions
- DRUG rhC1INH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2018-06-30 |
| Est. Completion | 2021-07-31 |
What the finished NCT03697187 record still lists
NCT03697187 is an observational study that tracks outcomes without assigning an intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which rhC1INH is the first listed.
NCT03697187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03697187 about?
NCT03697187 is a clinical study titled "Patient Registry to Evaluate the Real-world Safety of Ruconest®". This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.
What is the current status of trial NCT03697187?
This trial is currently completed. The enrollment target is 152 participants. The study started on 2018-06-30. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03697187?
The interventions under investigation include: rhC1INH (DRUG).
Who is sponsoring clinical trial NCT03697187?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI